Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Patients undergoing spinal fusion surgery with bone morphogenetic protein (BMP) appear to be at increased risk of benign tumors - but not cancers, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Dr. Nandan Lad of Duke University Medical Center and colleagues analyzed the risk of cancers and benign tumors in nearly 4,700 patients receiving BMP as part of spinal fusion surgery. Bone morphogenetic protein is a growth factor that can promote new bone formation. It is FDA-approved for one specific type of spinal fusion surgery, but has become widely used "off-label" for other fusion procedures.
Contrary to previous smaller studies, patients receiving BMP as commonly used today, had no increase in systemic or malignant cancer risk, compared to a matched group undergoing spinal fusion without BMP. However, spinal fusion with BMP was associated with a higher risk of benign tumors: about 30% higher, after adjustment for other factors.
Although absolute risks were small, patients receiving BMP had a higher rate of benign tumors of the nervous system - especially of the tissues lining the spinal cord and brain (meninges). The increase in these soft tissue tumors may be related to the "large local dose" of BMP around the spine, the researchers suspect. The results of this large, independent, propensity-matched study suggest that the use of BMP in lumbar fusions is associated with a significantly higher rate of benign neoplasms, but not malignancies.
Cancer After Spinal Fusion: The Role of Bone Morphogenetic Protein, doi: 10.1227/NEU.0000000000000018
Wolters Kluwer Health
Article adapted by Medical News Today from original press release. Source:
Wolters Kluwer Health
Please use one of the following formats to cite this article in your essay, paper or report:
Health, Wolters Kluwer. "Bone growth factor may increase benign tumors but not malignant cancer." Medical News Today. MediLexicon, Intl., 10 Sep. 2013. Web.
11 Dec. 2013. <http://www.medicalnewstoday.com/releases/265843>
Health, W. (2013, September 10). "Bone growth factor may increase benign tumors but not malignant cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265843.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.